Literature DB >> 26700593

Podoplanin expression is correlated with the prognosis of lung squamous cell carcinoma.

Yoichiro Ikoma1, Hiroshi Kijima, Ryota Masuda, Makiko Tanaka, Sadaki Inokuchi, Masayuki Iwazaki.   

Abstract

Podoplanin is a 38 kDa transmembrane protein that is involved in cell migration and cancer cell invasion. Some studies have reported that podoplanin expression was correlated with poor prognosis in lung squamous cell carcinoma (SqCC). However, there have been no clinicopathological studies of podoplanin membrane expression and localization in lung SqCC. In this study, we focused on the intensity and localization of podoplanin membrane expression, and its clinicopathological significance for lung SqCC. Strong membrane expression of podoplanin was significantly associated with lymph node metastasis, lymphatic invasion, and histological differentiation. Cases with strong podoplanin expression at cell membrane showed better prognosis of lung SqCC (HR, 3.301). Peripheral localization of podoplanin was associated with tumor size, lymphatic invasion, and histological differentiation. Cases with peripheral podoplanin expression showed favorable prognosis of lung SqCC (HR, 2.830). Both strong membrane expression and peripheral expression of podoplanin were independent predictors of mortality of lung SqCC (HR, 2.869; HR, 2.443, respectively). The cases with strong or peripheral podoplanin expression showed better overall survival (P = 0.001, both). Podoplanin intensity is significantly associated with podoplanin localization (P < 0.001), and its correlation coefficient was 0.678. We concluded that podoplanin membrane expression, not only its localization, is a useful prognostic indicator of lung SqCC patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26700593     DOI: 10.2220/biomedres.36.393

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  5 in total

1.  Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer.

Authors:  Oksana Kowalczuk; Jerzy Laudanski; Wojciech Laudanski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Jacek Niklinski
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

2.  Prognostic Value of Podoplanin in Various Tumors.

Authors:  Xiaohang Wang; Xueying Wang; Vladmir Carvalho; Qianqian Wang; Tingting Li; Jinbang Wang; Yang Chen; Chengming Ni; Subo Liu; Jiaxin Zhang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

3.  Co-expression of podoplanin and fibroblast growth factor 1 predicts poor prognosis in patients with lung squamous cell carcinoma.

Authors:  Juan Li; Han Chen; Xiaoqing Li; Linlin Wang; Aiqin Gao; Pei Zhang; Wenli Lin; Wei Gao; Dong Yang; Xiaosun Guo; Jie Liu; Qi Dang; Yuping Sun
Journal:  Mol Med Rep       Date:  2017-06-21       Impact factor: 2.952

4.  Podoplanin is a useful prognostic marker and indicates better differentiation in lung squamous cell cancer patients? A systematic review and meta-analysis.

Authors:  Liya Hu; Peng Zhang; Qi Mei; Wei Sun; Lei Zhou; Tiejun Yin
Journal:  BMC Cancer       Date:  2020-05-14       Impact factor: 4.430

Review 5.  Platelet-activating factor podoplanin: from discovery to drug development.

Authors:  Ai Takemoto; Kenichi Miyata; Naoya Fujita
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.